Systemic mastocytosis – Patient Worthy

source: shutterstock.com

Rare Community Profiles: What’s Your SMthing?: Pam’s Efforts to Create a Culture of Support and Awareness for Systemic Mastocytosis

Post author:Jessica Lynn
Post published:June 28, 2023
Post category:Systemic mastocytosis

Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Photo courtesy of Tracy Kyttle

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 3)

Post author:Jessica Lynn
Post published:February 28, 2023
Post category:mastocytosis Systemic mastocytosis Timely

Ready to read? Before you do, make sure to check out Parts 1 and 2 of Tracy's story. In Part 1, Tracy describes the symptoms that led her to pursue a diagnosis. Part 2…

Photo courtesy of Tracy Kyttle

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 2)

Post author:Jessica Lynn
Post published:February 27, 2023
Post category:mastocytosis Systemic mastocytosis

Before you read on, make sure to check out Part 1 of Tracy's story. In Part 1, Tracy discusses the symptoms that led her to pursue a diagnosis and the multi-year diagnostic…

Photo courtesy of Tracy Kyttle

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 1)

Post author:Jessica Lynn
Post published:February 23, 2023
Post category:mastocytosis Systemic mastocytosis

Ten years ago, Tracy Kyttle moved from New England to the DC Metro Area to pursue a career in education leadership. She loved the area’s duality: its proximity to nature…

Positive Data Reported From Clinical Trial for Advanced Systemic Mastocytosis

Post author:Trudy Horsting
Post published:June 22, 2022
Post category:Systemic mastocytosis

Cogent Biosciences has just released promising initial data from their Phase 2 clinical trial called APEX. This trial is investigating bezuclastinib, a selective KIT D816V inhibitor, as a treatment for…

source: pixabay.com

Study Finds Systemic Mastocytosis Patients Without CMIHR History Don’t Need Premedication Prior to Imaging

Post author:Trudy Horsting
Post published:November 26, 2021
Post category:Systemic mastocytosis

Results from a study on systemic mastocytosis (SM) have recently been published. This investigation aimed to understand the prevalence of contrast media induced hypersensitivity reactions (CMIHR) in different subtypes of…

The First Successful Treatment for Systemic Mastocytosis Has Been Approved by the FDA

Post author:Rose Duesterwald
Post published:June 21, 2021
Post category:Systemic mastocytosis

According to a recent article in Biospace, patients with advanced systemic mastocytosis (SM) can turn to a newly FDA-approved treatment by Blueprint Medicines called Ayvakit (avapritinib). The drug is the…

Cripplepalooza Gives Artists and Comedians An Accessible Stage

Post author:Sunniva Bean
Post published:May 31, 2021
Post category:mastocytosis Systemic mastocytosis

As the pandemic closed bars and theaters and so many of our jobs became remote, much of the world became virtual. And as cocktail hour moved onto zoom and museums…

https://unsplash.com/photos/VQd9wPl4b_g

Mastocytosis Worsens Venom Allergy Outcomes

Post author:Jessica Lynn
Post published:May 20, 2021
Post category:mastocytosis Systemic mastocytosis

The first time I got stung by a wasp, my knee swelled up to nearly 4x its size. While my allergy is more frustrating than fatal, I know that I…

source: pixabay.com

Recruitment Is Going Well in Ayvakit Trial for Systemic Mastocytosis

Post author:Kendall Mason
Post published:May 17, 2021
Post category:Systemic mastocytosis

According to an article in Clinical Trials Arena, Blueprint Medicine has been steadily and speedily recruiting participants for its Phase II PIONEER trial, which examines Ayvakit as a treatment for…

source: shutterstock

Rare Classroom: Systemic Mastocytosis

Post author:James Moore
Post published:April 21, 2021
Post category:Systemic mastocytosis

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review

Post author:Trudy Horsting
Post published:January 7, 2021
Post category:Systemic mastocytosis

Blueprint Medicines Corporation has just announced that they have submitted a supplemental New Drug Application (NDA) to the FDA. This application is for a therapy called AYVAKIT, which was developed…

ASH Annual Meeting: Multiple Presentations on AYVAKIT for SM

Post author:Jessica Lynn
Post published:November 30, 2020
Post category:Systemic mastocytosis

The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will be held virtually this year from December 5 through 8. The goal of the meeting is to provide…

source: pixabay.com

Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis

Post author:Jessica Lynn
Post published:September 25, 2020
Post category:Systemic mastocytosis

In a recent press release, precision therapy company Blueprint Medicines Corporation announced positive results from two clinical trials: EXPLORER and PATHFINDER. The trials examined the safety, efficacy, and tolerability…

source: pixabay.com

The Latest Advances in Systemic Mastocystosis Molecular Biology Could Change Future Treatment

Post author:Patient Worthy Contributor
Post published:July 31, 2020
Post category:Systemic mastocytosis

By Lauren Thayer from In The Cloud Copy Systemic mastocytosis (SM) is a complicated condition of the blood in which excessive numbers of mast cells (a type of white blood…

source: pixabay.com

The Drug Avapritinib Shows Potential for Treating Systemic Mastocytosis

Post author:James Moore
Post published:March 25, 2020
Post category:Rare Disease Systemic mastocytosis

According to a story from mdmag.com, a phase 2 trial testing the drug avapritinib as a treatment for systemic mastocytosis is currently ongoing. The results so far suggest that the…

source: pixabay.com

Study: Avapritinib Shows No Adverse Effects in Phase II Trial for Systematic Mastocytosis

Post author:Kendall Mason
Post published:December 12, 2019
Post category:Systemic mastocytosis

A PIONEER trial has been conducted in order to evaluate the effects of avapritinib, a drug meant to treat systematic mastocytosis. Researchers want to find a better treatment for…

qimono / Pixabay

Experimental Systemic Mastocytosis Treatment Displays Potential in Early Trials

Post author:James Moore
Post published:December 11, 2018
Post category:Rare Disease Systemic mastocytosis

According to a story from PR Newswire, the Blueprint Medicines Corporation recently announced that latest results from a Phase 1 clinical trial of avapritinib as a treatment for advanced systemic…

jarmoluk / Pixabay

Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released

Post author:Anna Hewitt
Post published:June 18, 2018
Post category:Systemic mastocytosis

Promising data from the ongoing Phase I clinical trial Explorer has been announced by Blueprint Medicines Corporation. The trial is designed to evaluate the effects of the experimental drug avapritinib…

Rare Community Profiles: What’s Your SMthing?: Pam’s Efforts to Create a Culture of Support and Awareness for Systemic Mastocytosis

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 3)

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 2)

Living with Systemic Mastocytosis: How Tracy Dares to be Rare (Pt. 1)

Positive Data Reported From Clinical Trial for Advanced Systemic Mastocytosis

Study Finds Systemic Mastocytosis Patients Without CMIHR History Don’t Need Premedication Prior to Imaging

The First Successful Treatment for Systemic Mastocytosis Has Been Approved by the FDA

Cripplepalooza Gives Artists and Comedians An Accessible Stage

Mastocytosis Worsens Venom Allergy Outcomes

Recruitment Is Going Well in Ayvakit Trial for Systemic Mastocytosis

Rare Classroom: Systemic Mastocytosis

Investigative Therapy to Treat Underlying Cause of Systemic Mastocytosis is Under FDA Review

ASH Annual Meeting: Multiple Presentations on AYVAKIT for SM

Positive Data Announced from AYVAKIT Clinical Trials for Systemic Mastocytosis

The Latest Advances in Systemic Mastocystosis Molecular Biology Could Change Future Treatment

The Drug Avapritinib Shows Potential for Treating Systemic Mastocytosis

Study: Avapritinib Shows No Adverse Effects in Phase II Trial for Systematic Mastocytosis

Experimental Systemic Mastocytosis Treatment Displays Potential in Early Trials

Data From a Phase I Study of a Drug to Treat Systemic Mastocytosis Has Been Released

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More